BioCentury | Apr 28, 2020
Finance

Merck’s adjusted revenue guidance shows product mix matters during COVID-19

...“If you look at 340B, the majority of the exposure really is for products like Januvia...
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...the future, and the company expects to continue exploring the cardiometabolic area. Diabetes drug Januvia sitagliptin...
BioCentury | Jan 2, 2020
Politics & Policy

Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

...apixaban by 6%, and Merck & Co. Inc. (NYSE:MRK) raised the list price of Januvia sitagliptin...
BioCentury | Nov 16, 2019
Company News

Nov. 15 Company Quick Takes: Qiagen continues climb after confirming takeout offers; plus Fetroja, selumetinib, PharmAbcine, semaglutide

...drug Rybelsus oral semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) is superior to Januvia sitagliptin...
BioCentury | Nov 13, 2019
Product Development

Hua Phase III diabetes data make good on glucokinase but disappoint investors

...to report Phase I data for its U.S. trials of dorzagliatin plus DPP-4 inhibitor Januvia sitagliptin...
...Co. (NYSE:LLY). The company will also start a Chinese Phase III study comparing dorzagliatin and Januvia...
BioCentury | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

...has a wholesale acquisition cost (WAC) of $772.43 per month. Oral diabetes drug competitors Januvia sitagliptin...
BioCentury | Jun 20, 2019
Company News

Beyond Keytruda: Merck details plans for future growth

...chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin...
...and provided insight into its appetite for M&A. "Everything we need to drive growth through Januvia...
...day Thursday. Merck & Co. Inc. (NYSE:MRK) recorded $5.9 billion in 2018 sales for the Januvia...
BioCentury | Feb 8, 2019
Clinical News

Hua starts U.S. Phase I trial of diabetes candidate

...began a Phase I trial of its dorzagliatin (sinogliatin, HMS5552, RO5305552) in combination with Januvia sitagliptin...
...a small molecule GCK activator, from Roche (SIX:ROG; OTCQX:RHHBY). Merck & Co. Inc. (NYSE:MRK) markets Januvia...
BioCentury | Sep 21, 2018
Politics, Policy & Law

Filling the rebate void

...I’m one of these consolidated payers and I’ve contracted with Merck & Co. Inc. for Januvia...
BioCentury | Jun 22, 2018
Clinical News

Novo's oral GLP-1 analog meets primary in Phase IIIa trials compared with approved therapies

...greater proportion of patients who achieved an HbA1c of <7% at week 52 vs. Januvia sitagliptin...
...for Januvia. Additionally, oral semaglutide significantly reduced body weight from baseline to week 52 vs. Januvia...
...Status: Phase IIIa data Milestone: Submit regulatory application (2019) Jennie Walters Glactiv, Januvia, Tesavel, sitagliptin (MK-0431, MK-431, ONO-5435) Jardiance...
Items per page:
1 - 10 of 345